The ORR was 63% (95%CI, 55%-71%) for patients with CLL or SLL, irrespective of whether patients previously discontinued a covalent BTK inhibitor for progression, toxicity or other reasons. Here, BTK is linked to B-cell chronic lymphocytic leukemia.